5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.45▼ | 2.44▲ | 2.43▲ | 2.43▲ | 2.20▲ |
MA10 | 2.45▼ | 2.43▲ | 2.44▲ | 2.35▲ | 2.54▼ |
MA20 | 2.44▲ | 2.43▲ | 2.41▲ | 2.22▲ | 3.32▼ |
MA50 | 2.43▲ | 2.38▲ | 2.34▲ | 2.63▼ | 7.35▼ |
MA100 | 2.43▲ | 2.33▲ | 2.27▲ | 3.34▼ | N/A |
MA200 | 2.39▲ | 2.23▲ | 2.24▲ | 6.60▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.001▼ | -0.002▼ | -0.001▼ | 0.070▲ | 0.201▲ |
RSI | 52.832▲ | 54.872▲ | 56.417▲ | 51.982▲ | 35.725▼ |
STOCH | 61.111 | 65.786 | 59.848 | 84.686▲ | 19.621▼ |
WILL %R | -28.571 | -40.909 | -20.455▲ | -9.615▲ | -74.085 |
CCI | -6.289 | 60.129 | 57.272 | 134.204▲ | -55.393 |
Thursday, April 24, 2025 05:00 PM
MOUNTAIN VIEW, Calif., April 22, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for ...
|
Thursday, April 24, 2025 05:00 PM
MOUNTAIN VIEW, Calif., April 22, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for ...
|
Tuesday, April 22, 2025 05:04 AM
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 2.50 | 2.50 | 2.38 | 2.45 | 148,500 |
30/04/25 | 2.41 | 2.50 | 2.27 | 2.49 | 134,900 |
29/04/25 | 2.33 | 2.455 | 2.30 | 2.455 | 126,970 |
28/04/25 | 2.36 | 2.41 | 2.28 | 2.41 | 151,200 |
25/04/25 | 2.25 | 2.35 | 2.20 | 2.35 | 141,650 |
24/04/25 | 2.28 | 2.336 | 2.24 | 2.28 | 100,100 |
23/04/25 | 2.33 | 2.46 | 2.26 | 2.27 | 149,400 |
22/04/25 | 2.37 | 2.37 | 2.14 | 2.26 | 344,500 |
21/04/25 | 2.23 | 2.33 | 2.17 | 2.32 | 183,500 |
17/04/25 | 2.19 | 2.27 | 2.15 | 2.26 | 148,800 |
|
|
||||
|
|
||||
|
|